624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas

Conclusion cited from the abstract: 

DDGP regimen produced prolonged survival, better tolerability and safety than SMILE regimen in newly diagnosed advanced ENKTL.

Double-click:

 

464

Conclusion cited from the abstract: Numerical PFS estimates favor the use of SCT in PTCL pts in a CR after A+CHP; however, sample sizes are small. It is also recognized that unknown confounders may impact this post-hoc analysis. We observed that use of SCT was infrequent in Asian countries, suggesting regional practice differences. The overall impact of consolidative SCT remains unconfirmed, including in patients treated with A+CHP. Further studies are needed to establish its role in this setting.

Double-click:
 

 

Conclusion cited from the abstract: In this phase 1b study, the combination of oral Nstat and VGCV was well tolerated in patients with EBV+ lymphomas, with no unexpected G3-G4 AE, and showed a very encouraging signal of efficacy, especially in HIV-negative patients, with CRs in BCL, TCL, and HL. The combination of Nstat and VGCV is a compelling targeted oral therapy for R/R EBV+ lymphomas of different lineage and histologic type and should be explored in other EBV+ malignancies. The phase 2a portion of this study is actively recruiting (NCT03397706).

Double-click:

 

466

Conclusion cited from the abstract: Cerdulatinib has shown good tolerability and clinical activity in PTCL and CTCL. Complete and durable responses across a spectrum of PTCL and CTCL subtypes were observed. Correlative studies are aimed at identifying predictors of response and resistance. This phase 2a study will inform the design of a pivotal trial in T-cell lymphoma.

 

467

Conclusion cited from the abstract: 

Nivolumab had modest clinical activity in patients with R/R PTCL and the study met the criteria at interim analysis to continue accrual. However, due to the high number of patients with hyperprogressive disease, the moderate activity of the drug, and short DOR, a decision was made to halt the study. These findings likely reflect the distinct biology of PTCL and should be considered when designing future studies using checkpoint inhibitors in these diseases. Further studies are indicated using nivolumab in combination (rather than a single-agent) and use of biomarkers to better predict the responders.

Double-click:

 

 

468

Conclusion cited from the abstract: 

The AITL and wt CXCL12 3’UTR cohorts met pre-specified statistical hypotheses supporting proof-of-concept for tipifarnib in PTCL. AITL histology, KIR3DL2 and CXCL12 genotype provided robust tools for the selection/stratification of PTCL subjects treated with tipifarnib. Extended enrollment of AITL patients continues and an update on enrollment and outcomes will be provided at the time of the presentation.